Therapies that inhibit angiogenesis are attracting fresh interest in combination regimens with immune checkpoint immunotherapy in tumor types such as hepatocellular carcinoma, urothelial carcinoma, and endothelial cancer.
More From BioPortfolio on "Combos Pairing Inhibitors of Angiogenesis and Immune Checkpoints Have Potential"